A1 Refereed original research article in a scientific journal
Low-Grade Adenosquamous Carcinoma of the Breast: A Single-Center Retrospective Study and a Systematic Literature Review
Authors: Tamminen, Anselm; Bostrom, Pia
Publisher: MDPI
Publishing place: BASEL
Publication year: 2024
Journal:: Cancers
Journal name in source: CANCERS
Journal acronym: CANCERS
Article number: 4246
Volume: 16
Issue: 24
Number of pages: 12
eISSN: 2072-6694
DOI: https://doi.org/10.3390/cancers16244246
Web address : https://doi.org/10.3390/cancers16244246
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/478092320
(1) Low-grade adenosquamous carcinoma (LGASC) is a rare subtype of metaplastic breast carcinoma (MpBC), accounting for fewer than 0.05% of breast cancer cases. Unlike the typically aggressive nature of MpBCs, LGASC is an indolent tumor with an excellent prognosis. Due to its rarity, LGASC is frequently misdiagnosed, particularly in core needle biopsies. Currently, there are no clear treatment guidelines for LGASC. (2) Methods: This study presents a single-center retrospective analysis and a systematic literature review of LGASC. (3) Results: Three LGASC cases were diagnosed among 6462 breast cancer patients in our center, demonstrating its rarity. LGASC has overlapping features with benign sclerosing lesions and is often initially misdiagnosed. LGASC is often overtreated, as its indolent nature is not recognized. It very rarely presents axillary or distant metastases, and in contemporary data, local recurrences are rare, questioning the need for adjuvant therapy. (4) Conclusions: LGASC is a very rare form of breast cancer with an excellent prognosis despite being MpBC and usually a triple-negative breast cancer. It is often overtreated as its unique nature is not recognized.
Downloadable publication This is an electronic reprint of the original article. |  |
Funding information in the publication:
The study was supported by a grant from the Turku University Foundation. The funding source has had no role in the design, conducting, analysis, or reporting of the study (Grant identifier 081819).
